Details for New Drug Application (NDA): 210673
✉ Email this page to a colleague
NDA 210673 describes EZETIMIBE, which is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Ani Pharms, Aurobindo Pharma Usa, and Dr Reddys Labs Sa, and is included in twenty-three NDAs. It is available from twenty-seven suppliers. Additional details are available on the EZETIMIBE profile page.
The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
Summary for 210673
| Tradename: | EZETIMIBE |
| Applicant: | Sciegen Pharms Inc |
| Ingredient: | ezetimibe |
| Patents: | 0 |
Pharmacology for NDA: 210673
| Physiological Effect | Decreased Cholesterol Absorption |
Medical Subject Heading (MeSH) Categories for 210673
Suppliers and Packaging for NDA: 210673
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EZETIMIBE | ezetimibe | TABLET;ORAL | 210673 | ANDA | ScieGen Pharmaceuticals Inc | 50228-379 | 50228-379-05 | 500 TABLET in 1 BOTTLE (50228-379-05) |
| EZETIMIBE | ezetimibe | TABLET;ORAL | 210673 | ANDA | ScieGen Pharmaceuticals Inc | 50228-379 | 50228-379-10 | 1000 TABLET in 1 BOTTLE (50228-379-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Oct 23, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
